These studies collectively highlight the significant role of exosome-mediated purine metabolic disorders and lysosomal dysfunction in the progression of gout, laying the theoretical foundation for CTSD and HPRT1 as biomarkers for diagnosing gouty arthritis clinically and developing therapeutic strategies targeting exosomes. Here, CTSD is linked to gout.